Product Description
CB-020 is a iNK cell candidate for the treatment of solid tumors. (Sourced from: https://www.cariboubio.com/pipeline/)
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: CAR-T
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Caribou Biosciences
Company Location: BERKELEY CA 94710
Company CEO: Rachel E. Haurwitz
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/12/2022 |
News Article |
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy |